VRAXVirax Biolabs Group Ltd

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire LONDON, July 10, 2026 LONDON, July 10, 2026...

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire LONDON, July 9, 2026 LONDON, July 9, 2026 /PRNewswire/ -- Virax...

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX) stock roseread more...

A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government contracts and enterprise AI initiatives, several companies confirm strengthening revenue opportunities and long-term execution. $BLIS, $VRAX, $ENVX, $RKTO, $SPCX, $TDTH

Virax Biolabs (NASDAQ:VRAX) has taken a meaningful step from product development toward commercial execution by signing an exclusive multi-country commercial supply agreement with Fosun Diagnostics, one of Asia's largest diagnostics organizations. While still an emerging biotechnology company, Virax is now positioned to begin generating near-term revenue from its commercially available ImmuneSelect research-use product line while continuing to develop its flagship ViraxImmune diagnostic platform.

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stockread more...

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics PR Newswire LONDON, July 9, 2026 LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the...

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation PR Newswire LONDON, June 24, 2026 LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that...

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes PR Newswire LONDON, May 26, 2026 LONDON, May 26...